Abstract
Urinary tract infection (UTI) is among the most common infectious diseases of humans and is the most common nosocomial infection in the developed world. They cause significant morbidity and mortality, with approximately 150 million cases globally per year. It is estimated that 40-50% of women and 5% of men will develop a UTI in their lifetime, and UTI accounts for more than 1 million hospitalizations and $1.6 billion in medical expenses each year in the USA. Uropathogenic E. coli (UPEC) is the primary cause of UTI. This review presents an overview of the primary virulence factors of UPEC, the major host responses to infection of the urinary tract, the emergence of specific multidrug resistant clones of UPEC, antibiotic treatment options for UPEC-mediated UTI and the current state of vaccine strategies as well as other novel anti-adhesive and prophylactic approaches to prevent UTI. New and emerging themes in UPEC research are also discussed in the context of future outlooks.
Keywords: Antibiotic resistance, uropathogenic Escherichia coli, vaccine, virulence, Urinary Tract Infection, UPEC, UTI, bladder infection (cystitis), acute kidney infection (pyelonephritis), pathogens.
Current Drug Targets
Title:Uropathogenic Escherichia coli Mediated Urinary Tract Infection
Volume: 13 Issue: 11
Author(s): Makrina Totsika, Danilo Gomes Moriel, Adi Idris, Benjamin A. Rogers, Daniel J. Wurpel, Minh-Duy Phan, David L. Paterson and Mark A. Schembri
Affiliation:
Keywords: Antibiotic resistance, uropathogenic Escherichia coli, vaccine, virulence, Urinary Tract Infection, UPEC, UTI, bladder infection (cystitis), acute kidney infection (pyelonephritis), pathogens.
Abstract: Urinary tract infection (UTI) is among the most common infectious diseases of humans and is the most common nosocomial infection in the developed world. They cause significant morbidity and mortality, with approximately 150 million cases globally per year. It is estimated that 40-50% of women and 5% of men will develop a UTI in their lifetime, and UTI accounts for more than 1 million hospitalizations and $1.6 billion in medical expenses each year in the USA. Uropathogenic E. coli (UPEC) is the primary cause of UTI. This review presents an overview of the primary virulence factors of UPEC, the major host responses to infection of the urinary tract, the emergence of specific multidrug resistant clones of UPEC, antibiotic treatment options for UPEC-mediated UTI and the current state of vaccine strategies as well as other novel anti-adhesive and prophylactic approaches to prevent UTI. New and emerging themes in UPEC research are also discussed in the context of future outlooks.
Export Options
About this article
Cite this article as:
Totsika Makrina, Gomes Moriel Danilo, Idris Adi, A. Rogers Benjamin, J. Wurpel Daniel, Phan Minh-Duy, L. Paterson David and A. Schembri Mark, Uropathogenic Escherichia coli Mediated Urinary Tract Infection, Current Drug Targets 2012; 13 (11) . https://dx.doi.org/10.2174/138945012803530206
DOI https://dx.doi.org/10.2174/138945012803530206 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
New Antibiotics for Severe ICU-Aquired Bacterial Infections
Infectious Disorders - Drug Targets Human Immunodeficiency Virus-Mononuclear Phagocyte Interactions:Emerging Avenues of Biomarker Discovery, Modes of Viral Persistence and Disease Pathogenesis
Current HIV Research Antibiotics in Endophthalmitis: Microbiological and Pharmacokinetic Considerations
Current Clinical Pharmacology New Advances in Infant Feeding: New Products and Novel Technologies
Recent Patents on Food, Nutrition & Agriculture Short- and Long-Term Survival of Nonsurgical Intensive Care Patients and its Relation to Diagnosis, Severity of Disease, Age and Comorbidities
Current Aging Science Current Evidence on the Evaluation and Management of Fever Without a Source in Infants Aged 0-90 Days: A Review
Reviews on Recent Clinical Trials Antibodies: Can They Protect Against HIV Infection?
Current Drug Targets - Infectious Disorders PEGylated Liposomal Vancomycin: A Glimmer of Hope for Improving Treatment Outcomes in MRSA Pneumonia
Recent Patents on Anti-Infective Drug Discovery Tuberculostatic Drugs Targeting Infections of the Central Nervous System
Anti-Infective Agents New Insights into the Immune Response to Pneumococci
Current Respiratory Medicine Reviews Extracellular Enzymes Production and Biofilm Formation in Rhodotorula Species
Current Enzyme Inhibition Brucella Pneumonia with Systemic Complications and Pancytopenia: A Case Report
Infectious Disorders - Drug Targets Use of Intravenous Immunoglobulin in the Treatment of Immune-Mediated Demyelinating Diseases of the Nervous System
Current Pharmaceutical Design Possible Protecting Role of TNF-α in Kainic Acid-induced Neurotoxicity Via Down-Regulation of NFκB Signaling Pathway
Current Alzheimer Research Kynurenine Pathway and Disease: An Overview
CNS & Neurological Disorders - Drug Targets Currently Used Biologic Agents in the Management of Behcet’s Syndrome
Current Medicinal Chemistry Synthesis and Biological Activity of Unnatural Enediynes
Current Medicinal Chemistry Adverse Systemic Reactions of Antihistamines: Highlights in Sedating Effects, Cardiotoxicity and Drug Interactions
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents The Neuropharmacology of Cluster Headache and other Trigeminal Autonomic Cephalalgias
Current Neuropharmacology Honey: The Natural ‟Inhibine”
Anti-Infective Agents